Spiriva, marketed by Pfizer and Boehringer Ingelheim, offered no advantage over an inhaled placebo for moderate-to-very-severe chronic obstructive pulmonary disease, or COPD, researchers reported on Sunday.
More
Also, remember this.
Looks like Spiriva might be the next Vytorin - sales-wise!
No comments:
Post a Comment